Fig. 3: Genomic alterations in pre-treatment tumor tissue and association with clinical outcomes. | Nature Medicine

Fig. 3: Genomic alterations in pre-treatment tumor tissue and association with clinical outcomes.

From: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Fig. 3: Genomic alterations in pre-treatment tumor tissue and association with clinical outcomes.

Oncoplot revealing frequently mutated genes based on DNA sequencing of pre-treatment transurethral resection of bladder tumor specimens among 73 patients. Oncoplot is arranged according to TMB (Methods) and annotated based on the presence or absence of a mutation in a pre-specified set of genes (RB1, ATM, ERCC2 and FANCC), referred to as ‘Signature_mutations’ and according to cCR categorization. Mutations are annotated: del, deletion; ins, insertion.

Back to article page